243 related articles for article (PubMed ID: 29288121)
1. Contemporary Incidence and Outcomes of Prostate Cancer Lymph Node Metastases.
Bernstein AN; Shoag JE; Golan R; Halpern JA; Schaeffer EM; Hsu WC; Nguyen PL; Sedrakyan A; Chen RC; Eggener SE; Hu JC
J Urol; 2018 Jun; 199(6):1510-1517. PubMed ID: 29288121
[TBL] [Abstract][Full Text] [Related]
2. Incidence of positive pelvic lymph nodes in patients with prostate cancer, a prostate-specific antigen (PSA) level of < or =10 ng/mL and biopsy Gleason score of < or =6, and their influence on PSA progression-free survival after radical prostatectomy.
Weckermann D; Goppelt M; Dorn R; Wawroschek F; Harzmann R
BJU Int; 2006 Jun; 97(6):1173-8. PubMed ID: 16686707
[TBL] [Abstract][Full Text] [Related]
3. Rise in Node-Positive Prostate Cancer Incidence in Context of Evolving Use and Extent of Pelvic Lymphadenectomy.
Taylor MA; Alemozaffar M; Master VA; Sanda MG; Filson CP
Clin Genitourin Cancer; 2019 Jun; 17(3):e494-e504. PubMed ID: 30819637
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of lymph nodal metastases in prostate cancer.
Gervasi LA; Mata J; Easley JD; Wilbanks JH; Seale-Hawkins C; Carlton CE; Scardino PT
J Urol; 1989 Aug; 142(2 Pt 1):332-6. PubMed ID: 2501518
[TBL] [Abstract][Full Text] [Related]
5. The incidence of lymph node metastases in prostate carcinoma depends not only on tumor characteristics but also on surgical performance and extent of pelvic lymphadenectomy.
Klevecka V; Musch M; Roggenbuck U; Stoerkel S; Kroepfl D
Medicina (Kaunas); 2008; 44(8):601-8. PubMed ID: 18791337
[TBL] [Abstract][Full Text] [Related]
6. Extent of lymph node dissection improves survival in prostate cancer patients treated with radical prostatectomy without lymph node invasion.
Preisser F; Bandini M; Marchioni M; Nazzani S; Tian Z; Pompe RS; Fossati N; Briganti A; Saad F; Shariat SF; Heinzer H; Huland H; Graefen M; Tilki D; Karakiewicz PI
Prostate; 2018 May; 78(6):469-475. PubMed ID: 29460290
[TBL] [Abstract][Full Text] [Related]
7. Fluorescence Guided Targeted Pelvic Lymph Node Dissection for Intermediate and High Risk Prostate Cancer.
Hruby S; Englberger C; Lusuardi L; Schätz T; Kunit T; Abdel-Aal AM; Hager M; Janetschek G
J Urol; 2015 Aug; 194(2):357-63. PubMed ID: 25896557
[TBL] [Abstract][Full Text] [Related]
8. Number of metastatic lymph nodes as determinant of outcome after salvage radical prostatectomy for radiation-recurrent prostate cancer.
Gugliemetti G; Sukhu R; Conca Baenas MA; Meeks J; Sjoberg DD; Eastham JA; Scardino PT; Touijer K
Actas Urol Esp; 2016 Sep; 40(7):434-9. PubMed ID: 27184342
[TBL] [Abstract][Full Text] [Related]
9. Predicting the risk of pelvic node involvement among men with prostate cancer in the contemporary era.
Nguyen PL; Chen MH; Hoffman KE; Katz MS; D'Amico AV
Int J Radiat Oncol Biol Phys; 2009 May; 74(1):104-9. PubMed ID: 19286330
[TBL] [Abstract][Full Text] [Related]
10. Is pelvic lymph node dissection necessary in patients with biopsy proven Gleason 6 prostate cancer? - analysis of the SEER database.
Daugherty M; Sedaghatpour D; Bratslavsky G; Shapiro O
Can J Urol; 2018 Aug; 25(4):9414-9420. PubMed ID: 30125522
[TBL] [Abstract][Full Text] [Related]
11. Pathological and oncologic outcomes for men with positive lymph nodes at radical prostatectomy: The Johns Hopkins Hospital 30-year experience.
Pierorazio PM; Gorin MA; Ross AE; Feng Z; Trock BJ; Schaeffer EM; Han M; Epstein JI; Partin AW; Walsh PC; Bivalacqua TJ
Prostate; 2013 Nov; 73(15):1673-80. PubMed ID: 24019101
[TBL] [Abstract][Full Text] [Related]
12. Importance of non-regional lymph nodes in assigning risk in primary metastatic prostate cancer.
Ali A; Hoyle A; Mistry H; Clarke NW
BJU Int; 2019 Jan; 123(1):65-73. PubMed ID: 29777564
[TBL] [Abstract][Full Text] [Related]
13. Outcomes after radical prostatectomy for patients with clinical stages T1-T2 prostate cancer with pathologically positive lymph nodes in the prostate-specific antigen era.
Dorin RP; Lieskovsky G; Fairey AS; Cai J; Daneshmand S
Urol Oncol; 2013 Nov; 31(8):1441-7. PubMed ID: 22516714
[TBL] [Abstract][Full Text] [Related]
14. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
[TBL] [Abstract][Full Text] [Related]
15. A preoperative nomogram identifying decreased risk of positive pelvic lymph nodes in patients with prostate cancer.
Cagiannos I; Karakiewicz P; Eastham JA; Ohori M; Rabbani F; Gerigk C; Reuter V; Graefen M; Hammerer PG; Erbersdobler A; Huland H; Kupelian P; Klein E; Quinn DI; Henshall SM; Grygiel JJ; Sutherland RL; Stricker PD; Morash CG; Scardino PT; Kattan MW
J Urol; 2003 Nov; 170(5):1798-803. PubMed ID: 14532779
[TBL] [Abstract][Full Text] [Related]
16. The impact of definitive local therapy for lymph node-positive prostate cancer: a population-based study.
Rusthoven CG; Carlson JA; Waxweiler TV; Raben D; Dewitt PE; Crawford ED; Maroni PD; Kavanagh BD
Int J Radiat Oncol Biol Phys; 2014 Apr; 88(5):1064-73. PubMed ID: 24661660
[TBL] [Abstract][Full Text] [Related]
17. Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era.
Boorjian SA; Thompson RH; Siddiqui S; Bagniewski S; Bergstralh EJ; Karnes RJ; Frank I; Blute ML
J Urol; 2007 Sep; 178(3 Pt 1):864-70; discussion 870-1. PubMed ID: 17631342
[TBL] [Abstract][Full Text] [Related]
18. Detecting lymph nodes metastasis in prostate cancer through extended vs. standard laparoscopic pelvic lymphadenectomy.
Arenas LF; Füllhase C; Boemans P; Fichtner J
Aktuelle Urol; 2010 Jan; 41 Suppl 1():S10-4. PubMed ID: 20094944
[TBL] [Abstract][Full Text] [Related]
19. Trends in incidence and 5-year mortality in men with newly diagnosed, metastatic prostate cancer-A population-based analysis of 2 national cohorts.
Helgstrand JT; Røder MA; Klemann N; Toft BG; Lichtensztajn DY; Brooks JD; Brasso K; Vainer B; Iversen P
Cancer; 2018 Jul; 124(14):2931-2938. PubMed ID: 29723398
[TBL] [Abstract][Full Text] [Related]
20. Histopathological characteristics of lymph node metastases predict cancer-specific survival in node-positive prostate cancer.
Boormans JL; Wildhagen MF; Bangma CH; Verhagen PC; van Leenders GJ
BJU Int; 2008 Dec; 102(11):1589-93. PubMed ID: 18710447
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
